{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:02:20Z","timestamp":1790456540872,"version":"4.1.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"am","delay-in-days":398,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100019192","name":"Center for Clinical and Translational Science, University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["UL1TR003096"],"award-info":[{"award-number":["UL1TR003096"]}],"id":[{"id":"10.13039\/100019192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["1K23HL143167"],"award-info":[{"award-number":["1K23HL143167"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["RAMOS22A0"],"award-info":[{"award-number":["RAMOS22A0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005227Y5123"],"award-info":[{"award-number":["005227Y5123"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["GUIMBE20A0-KB"],"award-info":[{"award-number":["GUIMBE20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016616","name":"Cystic Fibrosis Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK072482"],"award-info":[{"award-number":["DK072482"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["DK089507"],"award-info":[{"award-number":["DK089507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35HL135816"],"award-info":[{"award-number":["R35HL135816"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2025.03.010","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T04:40:23Z","timestamp":1742618423000},"page":"534-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0514-8536","authenticated-orcid":false,"given":"JS","family":"Guimbellot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashritha","family":"Chalamalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3512-3495","authenticated-orcid":false,"given":"KJ","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Dowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saly","family":"Abouelenein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8329-3958","authenticated-orcid":false,"given":"LE","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5340-5218","authenticated-orcid":false,"given":"J","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0735-4947","authenticated-orcid":false,"given":"G","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"EP","family":"Acosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KJ","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.03.010_bib0001","series-title":"Cystic Fibrosis Foundation Patient Registry Annual Data Report 2020","author":"Foundation","year":"2021"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1513\/AnnalsATS.201909-671CME","article-title":"The extrapulmonary effects of cystic fibrosis transmembrane conductance regulator modulators in cystic fibrosis","volume":"17","author":"Sergeev","year":"2020","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.010_bib0003","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jcf.2020.07.002","article-title":"Effect of highly effective modulator treatment on sinonasal symptoms in cystic fibrosis","volume":"20","author":"DiMango","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.010_bib0004","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1038\/ctg.2017.10","article-title":"Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation","volume":"8","author":"Gelfond","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-2522","article-title":"Growth in prepubertal children with cystic fibrosis treated with Ivacaftor","volume":"139","author":"Stalvey","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.jcf.2025.03.010_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(21)01429-6","article-title":"The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis","author":"Scully","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.010_bib0007","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1164\/rccm.201806-1018OC","article-title":"Rubenstein RC. Islet hormone and incretin secretion in cystic fibrosis after four months of ivacaftor therapy","volume":"199","author":"Kelly","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.03.010_bib0008","article-title":"CFTR modulator use is associated with higher hemoglobin levels in individuals with cystic fibrosis","author":"Gifford","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jcf.2020.11.008","article-title":"Investigators GO-e. Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation","volume":"20","author":"Guimbellot","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"155","key":"10.1016\/j.jcf.2025.03.010_bib0010","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"European Respiratory Review"},{"issue":"1","key":"10.1016\/j.jcf.2025.03.010_bib0011","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(15)00545-7","article-title":"Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2-5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study","volume":"4","author":"Davies","year":"2016","journal-title":"The lancet Respiratory medicine"},{"issue":"8","key":"10.1016\/j.jcf.2025.03.010_bib0013","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S2213-2600(16)30121-7","article-title":"Efficacy and safety of lumacaftor\/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis","volume":"4","author":"Elborn","year":"2016","journal-title":"The lancet Respiratory medicine"},{"key":"10.1016\/j.jcf.2025.03.010_bib0014","article-title":"Lumacaftor\/ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR","author":"Milla","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.03.010_bib0015","series-title":"The 30th Annual North American Cystic Fibrosis Conference","first-page":"S1","article-title":"Pediatric pulmonology","volume":"51","year":"2016"},{"key":"10.1016\/j.jcf.2025.03.010_bib0016","article-title":"Ivacaftor-elexacaftor-tezacaftor and tacrolimus combination in cystic fibrosis","author":"Smith","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.03.010_bib0017","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: a case series","author":"Ragan","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.010_bib0018","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ccr3.2053","article-title":"Lumacaftor\/ivacaftor initiation in two liver transplantation patients under tacrolimus and antifungal azoles","volume":"7","author":"Chouchane","year":"2019","journal-title":"Clin Case Rep"},{"key":"10.1016\/j.jcf.2025.03.010_bib0019","doi-asserted-by":"crossref","first-page":"e14007","DOI":"10.1111\/petr.14007","article-title":"To treat or not to treat: CFTR modulators after lung transplantation","author":"Hayes","year":"2021","journal-title":"Pediatr Transplant"},{"issue":"12","key":"10.1016\/j.jcf.2025.03.010_bib0020","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.healun.2021.08.009","article-title":"CFTR modulator use in post lung transplant recipients","volume":"40","author":"Benninger","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.jcf.2025.03.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2022.04.009","article-title":"Use of elexacaftor\/tezacaftor\/ivacaftor among cystic fibrosis lung transplant recipients","author":"Ramos","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.010_bib0022","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.jcf.2024.04.006","article-title":"Safety and efficacy of elexacaftor\/tezacaftor\/ivacaftor in people with Cystic Fibrosis following liver transplantation: a systematic review","volume":"23","author":"Testa","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.010_bib0023","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jcf.2024.01.008","article-title":"Elexacaftor\/tezacaftor\/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study","volume":"23","author":"van der Meer","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0024","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ppul.25779","article-title":"The use of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis postliver transplant: a case series","volume":"57","author":"Ragan","year":"2022","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2025.03.010_bib0025","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051438","article-title":"Application of physiologically based pharmacokinetic modeling to predict drug-drug interactions between Elexacaftor\/Tezacaftor\/Ivacaftor and Tacrolimus in lung transplant recipients","volume":"15","author":"Hong","year":"2023","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.jcf.2025.03.010_bib0026","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/phar.2710","article-title":"Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients","volume":"42","author":"Doligalski","year":"2022","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jcf.2025.03.010_bib0027","article-title":"A growing trend: CFTR modulators for cystic fibrosis lung transplant recipients","author":"Hayes","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.010_bib0028","doi-asserted-by":"crossref","first-page":"e14007","DOI":"10.1111\/petr.14007","article-title":"To treat or not to treat: CFTR modulators after lung transplantation","volume":"25","author":"Hayes","year":"2021","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jcf.2025.03.010_bib0029","doi-asserted-by":"crossref","DOI":"10.1097\/MCP.0000000000001110","article-title":"Elexacaftor-tezacaftor-ivacaftor use after solid organ transplant","author":"Kapnadak","year":"2024","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jcf.2025.03.010_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123518","article-title":"Quantitation of cystic fibrosis triple combination therapy, elexacaftor\/tezacaftor\/ivacaftor, in human plasma and cellular lysate","volume":"1213","author":"Ryan","year":"2022","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0031","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s41030-020-00124-7","article-title":"Physiologically based pharmacokinetic modeling of CFTR modulation in people with cystic fibrosis transitioning from mono or dual regimens to triple-combination Elexacaftor\/Tezacaftor\/Ivacaftor","volume":"6","author":"Tsai","year":"2020","journal-title":"Pulm Ther"},{"key":"10.1016\/j.jcf.2025.03.010_bib0032","series-title":"Multi-Discipline review application number 212273Orig1s000","year":"2019"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.010_bib0033","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1177\/1948550617697177","article-title":"Equivalence tests: a practical primer for t tests, correlations, and meta-analyses","volume":"8","author":"Lakens","year":"2017","journal-title":"Soc Psychol Personal Sci"},{"key":"10.1016\/j.jcf.2025.03.010_bib0034","series-title":"Drug approval package: trikafta food and drug administration","year":"2019"},{"issue":"1","key":"10.1016\/j.jcf.2025.03.010_bib0035","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jcf.2023.04.023","article-title":"Changes in liver biochemistry and tacrolimus levels following the introduction of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and liver transplant","volume":"23","author":"Tachtatzis","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"12","key":"10.1016\/j.jcf.2025.03.010_bib0036","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1002\/ppul.26396","article-title":"Use of CFTR modulators in special populations, part 3: solid organ transplant","volume":"58","author":"Kadouh","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jcf.2025.03.010_bib0037","article-title":"Impact of CFTR therapy on chronic rhinosinusitis and health status: deep learning CT analysis and patient reported outcomes","author":"Beswick","year":"2021","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0038","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/1945892418815615","article-title":"Ivacaftor, a cystic fibrosis transmembrane conductance regulator potentiator, enhances ciprofloxacin activity against Pseudomonas aeruginosa","volume":"33","author":"Cho","year":"2019","journal-title":"Am J Rhinol Allergy"},{"issue":"4","key":"10.1016\/j.jcf.2025.03.010_bib0039","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1177\/1945892419830624","article-title":"Decreased antibiotic utilization after sinus surgery in cystic fibrosis patients with lung transplantation","volume":"33","author":"Cheng","year":"2019","journal-title":"Am J Rhinol Allergy"},{"issue":"3","key":"10.1016\/j.jcf.2025.03.010_bib0040","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/lio2.401","article-title":"Chronic rhinosinusitis in patients with cystic fibrosis\u2014Current management and new treatments","volume":"5","author":"Johnson","year":"2020","journal-title":"Laryngoscope Investig. Otolaryngol."},{"issue":"10","key":"10.1016\/j.jcf.2025.03.010_bib0041","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.healun.2022.04.009","article-title":"Survival difference between high-risk and low-risk CFTR genotypes after lung transplant","volume":"41","author":"Clausen","year":"2022","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"10.1016\/j.jcf.2025.03.010_bib0042","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jcf.2021.11.012","article-title":"Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis","volume":"21","author":"Petersen","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"10212","key":"10.1016\/j.jcf.2025.03.010_bib0043","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"The Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2025.03.010_bib0044","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013tezacaftor\u2013ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2025.03.010_bib0045","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1513\/AnnalsATS.202108-969OC","article-title":"Body mass index recovery following lung transplant for cystic fibrosis","volume":"19","author":"Pryor","year":"2022","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2025.03.010_bib0046","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1275470","article-title":"Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jcf.2025.03.010_bib0047","unstructured":"Administration FaD. Drug approval package: trikafta food and drug administration [7\/30\/ 2020 ]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212273Orig1s000MultidisciplineR.pdf."},{"issue":"4","key":"10.1016\/j.jcf.2025.03.010_bib0048","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325000785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T05:18:34Z","timestamp":1749187114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325000785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":48,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199325000785"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.03.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}